Table 3.
Lung Cancer Mortality (Annualized %) by Randomization Group
| CEE plus MPA | Placebo | HR1 | (95% CI) | P-value | |||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | ||||
| Death from lung cancer2 | 73 | (0.11%) | 40 | (0.06%) | 1.71 | (1.16, 2.52) | 0.01 |
| Death from non-small cell lung cancer | 62 | (0.09%) | 31 | (0.05%) | 1.87 | (1.22, 2.88) | 0.004 |
| Death from small cell lung cancer | 11 | (0.02%) | 9 | (0.01%) | 1.16 | (0.48, 2.79) | 0.75 |
| Death after lung cancer diagnosis3 | 78 | (0.12%) | 49 | (0.08%) | 1.50 | (1.05, 2.14) | 0.03 |
| Death after non-small cell lung cancer | 67 | (0.10%) | 39 | (0.06%) | 1.61 | (1.09, 2.39) | 0.02 |
| Death after small cell lung cancer | 11 | (0.02%) | 10 | (0.02%) | 1.04 | (0.44, 2.46) | 0.92 |
1
HRs, 95% CIs and p-values are from Cox proportional hazards models stratified according to age, prior lung cancer, and DM trial randomization assignment.
2
Includes deaths after lung cancer diagnosis attributed to lung cancer
3
Follow-up starts at randomization and denominator includes all participants; includes all deaths after lung cancer diagnosis regardless of attributed etiology.